AstraZeneca touts separate late-stage lung cancer wins with Tagrisso, Enhertu

Phase 3positiveTagrissoOrpathysEnhertuPositive

AI Analysis

Summary

AstraZeneca reported positive Phase 3 trial results for two separate lung cancer treatments: a Tagrisso and Orpathys combination and its blockbuster antibody-drug conjugate Enhertu.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Late-stage trials reported successes in different forms of lung cancer with Tagrisso/Orpathys combination and Enhertu

Importance:7/10

Sentiment:

0.75

oncologylung cancerlate-stage trialpositive dataantibody-drug conjugate

Related Companies

$AZN

Read the original article

Published by Endpoints News on August 17, 2026 2:53 PM

Read Original